Insulin and IGF-1 receptor agonists and antagonists

Details Insulin and IGF-1 receptor agonists and antagonists Insulin and IGF-1 receptor agonists and antagonists

2005-04-05

2005-04-05

Celsa, Bennett (Department: 1639)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S003100, C514S013800, C514S017400, C530S300000, C530S303000, C530S326000, C530S330000

Reexamination Certificate

active

06875741

ABSTRACT:
Peptide sequences capable of binding to insulin and/or insulin-like growth factor receptors with either agonist or antagonist activity and identified from various peptide libraries are disclosed. This invention also identifies at least two different binding sites, which are present on insulin and insulin-like growth factor receptors, and which selectively bind the peptides of this invention. As agonists, certain of the peptides of this invention may be useful for development as therapeutics to supplement or replace endogenous peptide hormones. The antagonists may also be developed as therapeutics.

REFERENCES:
patent: 5652214 (1997-07-01), Lewis et al.
patent: 6403764 (2002-06-01), Dubaquie et al.
patent: 44 32 943 (1996-03-01), None
patent: 0 309 050 (1989-03-01), None
patent: WO 9308826 (1993-05-01), None
patent: WO 9323067 (1993-11-01), None
patent: WO 9707827 (1997-03-01), None
patent: WO 9746683 (1997-12-01), None
patent: WO 9928347 (1999-06-01), None
Wilson, R., et al., “2.2 MB of Contiguous Nucleotide Sequence from Chromosome III of C. Elegans”, Nature, GB, MacMillan Journals Ltd., London, vol. 368, No. 6466, 1994.
Database WPI, Section Ch., Week 199747, Derwent Publications Ltd., London, GB; An 1997-510880, XP002154566 & RU 2 078 769 C (A Med Biomed Chem Res Inst), 1997, Abstract.
Carroll PV, Umpleby M, Ward GS, Imuere S, Alexander E, Dunger D, Sonksen PH, and Russell-Jones DL (1997) rhIGF-I Administration Reduces Insulin Requirements, Decreases Growth Hormone Secretion, and Improves the Lipid Profile in Adults with IDDM. Diabetes 46:1453-1458.
Chen YCJ, Delbrook K, Dealwis C, Mimms L. Mushawar IK, and Mandecki W (1996) Discontinuous Epitopes of Hepatitis B Surface Antigen derived from a Filamentous Phage Peptide Library. Proc. Natl. Acad. Sci. U.S.A. 93:1997-2001.
Conover CA (1996) Regulation and Physiological Role of Insulin-Like Growth Factor Binding Proteins. Endocr. J. 43S:S43-S48.
Crowne EC, Samra JS, Cheetham T, Watts A, Holly JM, Dunger DB (1998) Recombinant Human Insulin-Like Growth Factor-I Abolishes Changes in Insulin Requirements Consequent Upon Growth Hormone Pulsatility in Young Adults with Type I Diabetes Mellitus. Metabolism 47:31-38.
De Meyts P, Wallach B, Christoffersen CT, Urdø B, Grønskov K, Latus L, Yakushiji F, Ilondo M, and Shymko RM. (1994) The Insulin-Like Growth Factor-1 Receptor Structure, Ligand-Binding Mechanism and Signal Transduction. Horm. Res. 42:152-169.*
Hoogenboom HR (1997) Designing and optimizing library selection strategies for generating high-affinity antibodies. Trends Biotechnol. 15:62-70.*
Kay BK, Adey NB, He YS, Manfredi JP, Mataragnon AH, and Fowlkes DM (1993) An M13 Phage Library Displaying Random 38-amino-acid Peptides as a Source of Novel Sequences with Affinity to Selected Targets. Gene 128:59-65.*
Mandecki W, Brissette R, Carcamo J, Cheng W, Dedova O, Hsiao KC, Moghe A, Ravera M, Shen H, Tang P, and Blume A (1997) Display Technologies—Novel Targets and Strategies, P, Guttry (Ed.). International Business Communications, Inc., Southborough, MA, pp. 231-254.*
Mynarcik DC, Williams PF, Schaffer L, Yu GQ, and Whittaker J (1997) Identification of Common Ligand Binding Determinants of the Insulin and Insulin-Like Growth Factor 1 Receptors. Insights in Mechanisms of Ligand Binding. J. Biol. Chem. 272:18650-18655.*
Rader C and Barbas CF III (1997) Phage Display of Combinatorial Antibody Libraries. Curr. Opin. Biotechnol. 8:503-508.*
Rajaram S, Baylink DJ, and Mohan S (1997) Insulin-Like Growth Factor-Binding Proteins in Serum and other Biological Fluids: Regulation and Functions. Endocr.Rev. 18:801-831.*
Ravera MW, Carcamo J, Brissette R, Alam-Moghe A, Dedova O, Cheng W, Hsiao KC, Klebanov D, Shen H, Tang P, Blume A, and Mandecki W (1998) Identification of an Allosteric Binding Site on the Transcription Factor p53 Using a Phage-Displayed Peptide Library. Oncogene 16:1993-1999.*
Yanofsky SD, Balldwin DN, Butler JH, Holden FR, Jacobs JW Balsubramanian P, Cinn JP, Cwirla SE, Petter-Bhatt E, Whitehorn EA, Akeson A, Bowlin TL, Dower WJ, and Barrett RW (1996) High affinity Type I Interleukin 1 Receptor Antagonists discovered by Screening Recombinant Peptide Libraries. Proc. Natl. Acad. Sci. U.S.A.93:7381-7386.*
Pillutla, RC, et al. (2002) Peptides Identify Critical Hotspots Involved in the Biological Activation of Insulin Receptor, J. Biol.Chem. 277:22590-22594.*
U.S. Appl. No. 09/146,127, filed Sep. 2, 1998, Beasley et al.*
U.S. Appl. No. 09/538,038, filed Mar. 29, 2000, Beasley et al.

Affiliated with

Also associated with

Rating

Insulin and IGF-1 receptor agonists and antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Insulin and IGF-1 receptor agonists and antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Insulin and IGF-1 receptor agonists and antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3420594